• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Hard To Treat Diseases (HTDS) Slavica BioChem Update on Research Activities

Posted on: Wednesday, 22 April 2009, 06:45 CDT

BELGRADE, April 22 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - HTDS chief scientist Dr. Sanja Pekovic provided updates from a recent medical convention held in Antwerpen; Joint Meeting 2009 Anatomische Gesellschaft - Nederlandse Anatomen Vereniging, Antwerpen, 27-30 March 2009.

Dr. Pekovic reported on the results of recent positive testing being conducted related to the CNS disorder multiple sclerosis and in suppression of reactive astrogliosis after brain injury. This led to a number of preliminary talks for future collaboration with other scientists working in the field. A more detailed review of the research results will be posted separately on the Pink Sheets as a supplementary filing shortly. Notably, this work was supported by the European Cooperation in the Field of Scientific and Technical Research (COST) organization.

Dr. Pekovic also reported the scientific team has started some in vitro studies of purine nucleoside analogues (ribavirin, tiazofurin, the drugs we are investigating) effects on microglial cell culture (there is no current data in the literature about their effect on microglia) in collaboration with professor Thomas Herdegen from Kiel University, Germany, who is also a member of COST as a representative of Germany. Over the last 3 months in the lab, our technicians have learned how to establish microglial cell culture, a valuable next step in the continued research.

HTDS will be providing additional funding to further this work, at the IBISS INSTITUT ZA BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC for Project 143005 headed by professor Mirjana Stojiljkovic.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com

SOURCE Hard to Treat Diseases

Source: PR Newswire

More News in this Category